Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

Jubilant Pharmova Limited, an integrated global Pharmaceutical Company, today announced that Jubilant Draximage Inc., a wholly owned subsidiary of the Company has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility at Montreal Canada in respect of the inspection conducted by the regulatory agency from June 6, 2022 to June 10, 2022.

With the receipt of the EIR, the inspection stands successfully closed.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 336.90 as compared to the previous close of Rs. 337.75. The total number of shares traded during the day was 12725 in over 941 trades.

The stock hit an intraday high of Rs. 343.00 and intraday low of 336.00. The net turnover during the day was Rs. 4307393.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 JubilantDraximage EIR USFDA Radiopharmaceuticals Montreal Canada